Avadel Pharmaceuticals plc(AVDL)Earnings, Financials & Key Ratios

AVDL•NASDAQ

$21.64

$2.1B mkt cap·Price updated Apr 24, 2026

SectorHealthcare IndustrySpecialty & Generic Pharma Sub-IndustryTherapy-focused branded biopharma

AboutAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Show more

Revenue$169M+504.8%
EBITDA-$40M+70.8%
Net Income-$49M+69.5%
EPS (Diluted)-0.51+74.5%
Gross Margin90.97%-6.2%
EBITDA Margin-23.49%+95.2%
Operating Margin-25.07%+94.9%
Net Margin-28.87%+95.0%
ROE-60.44%+87.4%
ROIC-76.28%+64.9%
Debt/Equity0.02-22.8%
Interest Coverage-3.91+71.9%

Technical→

AVDL Key Insights

Avadel Pharmaceuticals plc (AVDL) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 88 (top 12%)
✓Strong 5Y sales CAGR of 23.4%
✓Efficient asset utilization: 1.0x turnover

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 18.7% in last year
✗Expensive at 27.9x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

AVDL Price & Volume

Avadel Pharmaceuticals plc (AVDL) stock price & volume — 10-year historical chart

Loading chart...

AVDL Growth Metrics

Avadel Pharmaceuticals plc (AVDL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years27.6%

5 Years23.35%

3 Years-

TTM79.88%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM99.62%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM100.03%

Return on Capital

10 Years-24.76%

5 Years-52.87%

3 Years-78.15%

Last Year-34.86%

AVDL Recent Earnings

Avadel Pharmaceuticals plc (AVDL) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 4/12 qtrs (36%)●Beat Revenue 1/12 qtrs (10%)

Q2 2026Latest

Mar 2, 2026

EPS

$0.05

Est $0.08

-162.5%

Revenue

—

Est $80M

Q4 2025

Nov 4, 2025

EPS

—

Est $0.04

Revenue

$77M

Est $80M

-3.5%

Q3 2025

Aug 7, 2025

EPS

$0.10

Est $0.02

+400.0%

Revenue

$68M

Est $74M

-7.4%

Q2 2025

May 7, 2025

EPS

$0.05

Est $0.07

+28.6%

Revenue

$53M

Est $58M

-9.8%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Mar 2, 2026	$0.05vs $0.08-162.5%	—vs $80M
Q4 2025	Nov 4, 2025	—vs $0.04	$77Mvs $80M-3.5%
Q3 2025	Aug 7, 2025	$0.10vs $0.02+400.0%	$68Mvs $74M-7.4%
Q2 2025	May 7, 2025	$0.05vs $0.07+28.6%	$53Mvs $58M-9.8%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
JAZZJazz Pharmaceuticals plcDirect Competitor	14.34B	228.57	-39.14	4.88%	0.66%	0.71%	1.26
AXSMAxsome Therapeutics, Inc.Direct Competitor	11.46B	222.63	-60.50	65.55%	-26.59%	-260.01%	2.73
INVAInnoviva, Inc.Direct Competitor	1.91B	22.52	6.82	18.52%	118.91%	46.47%	0.23
SUPNSupernus Pharmaceuticals, Inc.Direct Competitor	2.96B	51.45	-75.66	8.63%	-3.74%	-2.73%	0.04
PGNYProgyny, Inc.Direct Competitor	1.53B	18.70	28.77	10.4%	4.54%	11.37%	0.05
NKTRNektar TherapeuticsProduct Competitor	1.67B	85.09	-8.75	-43.89%	-192.87%	-356.81%	0.95
COLLCollegium Pharmaceutical, Inc.Product Competitor	1.18B	36.51	21.10	23.62%	8.05%	24.11%	3.12
HALOHalozyme Therapeutics, Inc.Product Competitor	7.81B	66.35	25.92	37.55%	22.69%	6.49%

Compare AVDL vs Peers

Avadel Pharmaceuticals plc (AVDL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs JAZZ

Most directly comparable listed peer for AVDL.

Scale Benchmark

vs MCK

Larger-name benchmark to compare AVDL against a more recognizable public peer.

Peer Set

Compare Top 5

vs JAZZ, AXSM, INVA, SUPN

AVDL Income Statement

Avadel Pharmaceuticals plc (AVDL) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
Sales/Revenue	150.25M	172.74M	103.27M	59.22M	22.33M	0	0	27.96M	169.12M	248.52M
Revenue Growth %	-13.26%	14.97%	-40.22%	-42.66%	-62.28%	-100%	-	-	504.79%	79.88%
Cost of Goods Sold	13.25M	16.3M	17.52M	12.13M	5.74M	0	0	846K	15.28M	13.75M
COGS % of Revenue	8.82%	9.44%	16.96%	20.48%	25.71%	-	-	3.03%	9.03%	-
Gross Profit	137M▲ 0%	156.44M▲ 14.2%	85.75M▼ 45.2%	47.09M▼ 45.1%	16.59M▼ 64.8%	0▼ 100.0%	0▲ 0%	27.12M▲ 0%	153.84M▲ 467.3%	234.76M▲ 0%
Gross Margin %	91.18%	90.56%	83.04%	79.52%	74.29%	-	-	96.97%	90.97%	94.47%
Gross Profit Growth %	-15.58%	14.19%	-45.18%	-45.09%	-64.77%	-100%	-	-	467.32%	-
Operating Expenses	92.68M	96.74M	146.31M	71.2M	10.78M	85.55M	98.56M	164.97M	196.24M	230.24M
OpEx % of Revenue	61.68%	56%	141.68%	120.24%	48.25%	-	-	589.94%	116.04%	-
Selling, General & Admin	44.18M	58.86M	100.36M	30.18M	32.41M	68.5M	74.52M	151.71M	181.04M	190.35M
SG&A % of Revenue	29.4%	34.08%	97.18%	50.97%	145.09%	-	-	542.52%	107.05%	-
Research & Development	34.61M	34.22M	39.33M	32.92M	20.44M	17.1M	20.7M	13.26M	15.2M	39.89M
R&D % of Revenue	23.04%	19.81%	38.08%	55.59%	91.53%	-	-	47.42%	8.99%	-
Other Operating Expenses	-6.55M	2.08M	1.9M	8.1M	-42.07M	-53K	3.35M	0	0	0
Operating Income	-4.96M▲ 0%	88.3M▲ 1878.4%	-104.93M▼ 218.8%	-24.11M▲ 77.0%	5.82M▲ 124.1%	-85.55M▼ 1571.1%	-98.56M▼ 15.2%	-137.85M▼ 39.9%	-42.4M▲ 69.2%	4.52M▲ 0%
Operating Margin %	-3.3%	51.12%	-101.6%	-40.72%	26.04%	-	-	-492.97%	-25.07%	1.82%
Operating Income Growth %	-106.95%	1878.45%	-218.83%	77.02%	124.12%	-1571.13%	-15.21%	-39.86%	69.24%	-
EBITDA	9.52M	93.18M	-97.5M	-21.63M	7.5M	-84.73M	-97.07M	-136.08M	-39.72M	8.2M
EBITDA Margin %	6.34%	53.94%	-94.41%	-36.52%	33.6%	-	-	-486.65%	-23.49%	3.3%
EBITDA Growth %	-88.74%	878.4%	-204.63%	77.82%	134.7%	-1228.99%	-14.56%	-40.19%	70.81%	113.22%
D&A (Non-Cash Add-back)	14.49M	4.88M	7.43M	2.49M	1.69M	815K	1.49M	1.77M	2.68M	3.68M
EBIT	-8.76M	61.01M	-102.58M	-26.1M	7.91M	-83.2M	-99.1M	-150.89M	-38.25M	6.45M
Net Interest Income	-963K	-1.05M	-10.62M	-12.48M	-12.99M	-9.94M	-12.34M	-9.89M	-10.83M	-9.71M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	963K	1.05M	10.62M	12.48M	12.99M	9.94M	12.34M	9.89M	10.83M	9.71M
Other Income/Expense	-4.75M	3.15M	-8.27M	-14.47M	-10.9M	-7.6M	-12.88M	-22.93M	-6.68M	-7.78M
Pretax Income	-9.72M▲ 0%	91.47M▲ 1041.2%	-113.2M▼ 223.8%	-38.58M▲ 65.9%	-5.08M▲ 86.8%	-93.14M▼ 1732.8%	-111.44M▼ 19.6%	-160.78M▼ 44.3%	-49.08M▲ 69.5%	-3.26M▲ 0%
Pretax Margin %	-6.47%	52.95%	-109.61%	-65.16%	-22.75%	-	-	-574.96%	-29.02%	-1.31%
Income Tax	31.56M	24.21M	-17.89M	-5.36M	-12.11M	-15.82M	26.02M	-501K	-247K	-2.98M
Effective Tax Rate %	-324.74%	26.47%	15.81%	13.88%	238.29%	16.98%	-23.35%	0.31%	0.5%	91.46%
Net Income	-41.28M▲ 0%	67.25M▲ 262.9%	-95.3M▼ 241.7%	-33.23M▲ 65.1%	7.03M▲ 121.2%	-77.33M▼ 1200.3%	-137.46M▼ 77.8%	-160.28M▼ 16.6%	-48.83M▲ 69.5%	-278K▲ 0%
Net Margin %	-27.47%	38.93%	-92.29%	-56.11%	31.47%	-	-	-573.17%	-28.87%	-0.11%
Net Income Growth %	-201.52%	262.94%	-241.71%	65.14%	121.15%	-1200.3%	-77.77%	-16.59%	69.53%	99.62%
Net Income (Continuing)	-41.28M	68.27M	-95.3M	-33.23M	7.03M	-77.33M	-137.46M	-160.28M	-48.83M	-278K
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-1.00▲ 0%	1.61▲ 261.0%	-2.55▼ 258.4%	-0.89▲ 65.1%	0.13▲ 114.6%	-1.32▼ 1115.4%	-2.29▼ 73.5%	-2.00▲ 12.7%	-0.51▲ 74.5%	-0.00▲ 0%
EPS Growth %	-207.53%	261%	-258.39%	65.1%	114.61%	-1115.38%	-73.48%	12.66%	74.5%	100.03%
EPS (Basic)	-1.00	1.66	-2.55	-0.89	0.13	-1.32	-2.29	-2.00	-0.51	-
Diluted Shares Outstanding	41.25M	41.77M	37.33M	37.4M	54.94M	58.53M	60.09M	80.17M	95.14M	101.28M
Basic Shares Outstanding	41.25M	40.47M	37.33M	37.4M	53M	58.53M	60.09M	80.17M	95.14M	97.1M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

AVDL Balance Sheet

Avadel Pharmaceuticals plc (AVDL) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
Total Current Assets	181.19M	123.95M	124.85M	82.38M	263.45M	192.49M	100.84M	134.2M	134.21M	172.23M
Cash & Short-Term Investments	154.19M	94.08M	99.92M	64.16M	221.4M	157.22M	96.5M	105.11M	73.78M	91.58M
Cash Only	39.22M	16.56M	9.32M	9.77M	71.72M	50.71M	73.98M	31.17M	51.37M	79.81M
Short-Term Investments	114.98M	77.51M	90.59M	54.38M	149.68M	106.51M	22.52M	73.94M	22.41M	11.76M
Accounts Receivable	17.84M	16.51M	13.91M	11.97M	38.78M	31.54M	2.25M	12.1M	34.1M	42.44M
Days Sales Outstanding	43.34	34.88	49.17	73.81	633.81	-	-	157.98	73.59	58.29
Inventory	3.26M	6.16M	4.77M	3.57M	0	0	0	10.38M	20.3M	23.91M
Days Inventory Outstanding	89.76	137.86	99.4	107.47	-	-	-	4.48K	484.96	584.45
Other Current Assets	2.45M	128K	4.11M	561K	2.25M	550K	573K	2.23M	882K	798K
Total Non-Current Assets	64.3M	128.15M	65.45M	69.06M	48.18M	54.77M	31.94M	30.5M	30.03M	27.22M
Property, Plant & Equipment	3.32M	3M	7.8M	4.16M	2.96M	11.49M	13.24M	13.08M	12.86M	3.01M
Fixed Asset Turnover	45.25x	57.56x	13.23x	14.25x	7.54x	-	-	2.14x	13.16x	25.79x
Goodwill	18.49M	18.49M	18.49M	18.49M	16.84M	16.84M	16.84M	16.84M	16.84M	16.84M
Intangible Assets	22.84M	92.29M	1.63M	813K	0	0	0	0	0	0
Long-Term Investments	1.77M	1.4M	8.75M	0	0	0	0	0	0	0
Other Non-Current Assets	7.53M	9.1M	5.75M	16.17M	10.13M	2.33M	1.87M	579K	337K	8.11M
Total Assets	245.48M▲ 0%	252.11M▲ 2.7%	190.3M▼ 24.5%	151.44M▼ 20.4%	311.64M▲ 105.8%	247.26M▼ 20.7%	132.78M▼ 46.3%	164.7M▲ 24.0%	164.24M▼ 0.3%	199.45M▲ 0%
Asset Turnover	0.61x	0.69x	0.54x	0.39x	0.07x	-	-	0.17x	1.03x	1.38x
Asset Growth %	14.19%	2.7%	-24.52%	-20.42%	105.79%	-20.66%	-46.3%	24.03%	-0.28%	44.59%
Total Current Liabilities	62.42M	86.18M	38.38M	35.98M	15.11M	21M	55.79M	36.85M	48.83M	62.49M
Accounts Payable	7.11M	7.48M	3.5M	6.1M	2.93M	7.68M	7.89M	11.43M	7.33M	12.58M
Days Payables Outstanding	195.75	167.42	73	183.63	186.5	-	-	4.93K	175.08	259.67
Short-Term Debt	268K	111K	106K	645K	474K	0	37.67M	0	0	740K
Deferred Revenue (Current)	2.22M	2.01M	114K	0	0	0	0	0	0	0
Other Current Liabilities	48.33M	72.17M	29.74M	24.7M	10M	3.52M	1.91M	11.8M	21.01M	40.33M
Current Ratio	2.90x	1.44x	3.25x	2.29x	17.44x	9.17x	1.81x	3.64x	2.75x	2.75x
Quick Ratio	2.85x	1.37x	3.13x	2.19x	17.44x	9.17x	1.81x	3.36x	2.33x	2.33x
Cash Conversion Cycle	-62.65	5.33	75.57	-2.35	-	-	-	-296.33	383.47	383.07
Total Non-Current Liabilities	140.99M	81.37M	149.14M	144.65M	134.26M	148.02M	98.14M	40.1M	41.55M	38.74M
Long-Term Debt	547K	156K	115.73M	121.69M	128.21M	142.4M	91.61M	0	0	34.83M
Capital Lease Obligations	0	0	0	2.32M	1.84M	1.71M	780K	1.69M	1.12M	7.12M
Deferred Tax Liabilities	134.26M	72.28M	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	140.44M	81M	33.4M	20.65M	4.21M	3.92M	5.74M	38.41M	40.43M	120.67M
Total Liabilities	203.41M	167.54M	187.52M	180.63M	149.37M	169.02M	153.93M	76.96M	90.39M	101.22M
Total Debt	815K	267K	115.84M	124.65M	130.52M	145M	131.02M	2.62M	1.7M	37.38M
Net Debt	-38.4M	-16.3M	106.52M	114.88M	58.8M	94.3M	57.04M	-28.54M	-49.67M	-42.44M
Debt / Equity	0.02x	0.00x	41.67x	-	0.80x	1.85x	-	0.03x	0.02x	0.02x
Debt / EBITDA	0.09x	0.00x	-	-	17.39x	-	-	-	-	4.56x
Net Debt / EBITDA	-4.03x	-0.17x	-	-	7.84x	-	-	-	-	-5.18x
Interest Coverage	-5.16x	83.94x	-9.88x	-1.93x	0.45x	-8.60x	-7.99x	-13.94x	-3.91x	0.66x
Total Equity	42.07M▲ 0%	84.56M▲ 101.0%	2.78M▼ 96.7%	-29.2M▼ 1150.3%	162.27M▲ 655.7%	78.24M▼ 51.8%	-21.14M▼ 127.0%	87.74M▲ 514.9%	73.85M▼ 15.8%	98.22M▲ 0%
Equity Growth %	-38.01%	101.01%	-96.71%	-1150.32%	655.72%	-51.78%	-127.02%	514.94%	-15.83%	39.28%
Book Value per Share	1.02	2.02	0.07	-0.78	2.95	1.34	-0.35	1.09	0.78	0.97
Total Shareholders' Equity	42.07M	84.56M	2.78M	-29.2M	162.27M	78.24M	-21.14M	87.74M	73.85M	98.22M
Common Stock	414K	414K	427K	429K	583K	586K	628K	898K	965K	972K
Retained Earnings	-319.8M	-263.7M	-357.99M	-391.21M	-384.19M	-447.76M	-585.22M	-745.5M	-794.33M	-789.56M
Treasury Stock	0	-22.36M	-50M	-50M	0	0	0	0	0	0
Accumulated OCI	-23.57M	-23.27M	-23.42M	-22.81M	-21.05M	-23.94M	-26.34M	-23.17M	-24.58M	-23.58M
Minority Interest	0	0	0	0	0	0	0	0	0	0

AVDL Cash Flow Statement

Avadel Pharmaceuticals plc (AVDL) cash flow — operating, investing & free cash flow history

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
Cash from Operations	18.9M	16.66M	-82.72M	-38.33M	-48.73M	-77.31M	-70.3M	-128.51M	-46.91M	-46.91M
Operating CF Margin %	12.58%	9.65%	-80.1%	-64.72%	-218.21%	-	-	-459.58%	-27.74%	-
Operating CF Growth %	-77.58%	-11.85%	-596.43%	53.67%	-27.16%	-58.64%	9.06%	-82.79%	63.5%	807.78%
Net Income	-41.28M	67.25M	-95.3M	-33.23M	7.03M	-77.33M	-137.46M	-160.28M	-48.83M	-278K
Depreciation & Amortization	14.49M	4.88M	7.43M	2.49M	1.69M	815K	1.49M	1.77M	2.68M	3.68M
Stock-Based Compensation	14.68M	8.07M	7.85M	519K	3M	8.87M	7.01M	15.81M	20.39M	13.64M
Deferred Taxes	-4M	3.56M	-19.15M	-6.33M	-7.43M	-15.67M	26.02M	0	0	0
Other Non-Cash Items	33.7M	-69.53M	28.17M	-4.02M	-44.88M	2.3M	8.09M	17.19M	-828K	25.4M
Working Capital Changes	1.31M	2.42M	-11.71M	2.25M	-8.13M	3.69M	24.54M	-3M	-20.32M	-6.83M
Change in Receivables	-10.05M	3.08M	3.45M	1.46M	10.49M	2.8M	30K	-10.22M	-21.99M	-5.47M
Change in Inventory	1.83M	-2.9M	711K	1.16M	-1.35M	0	-30K	-9.53M	-9.22M	-8.06M
Change in Payables	-434K	596K	-2.03M	4.64M	-2.79M	4.23M	-3.11M	1.54M	-4.09M	4.62M
Cash from Investing	-36.63M	-15.7M	-36.98M	38.72M	-69.72M	56.93M	79.7M	-50.09M	51.78M	10.19M
Capital Expenditures	-1.2M	-53.7M	-20.18M	-29K	-98K	-26K	-716K	0	0	-191.76K
CapEx % of Revenue	0.8%	31.09%	19.54%	0.05%	0.44%	-	-	-	-	-
Acquisitions	628K	53.11M	20M	0	25.5M	16.5M	-80.41M	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-36.06M	-53.11M	-20M	154K	0	0	80.41M	0	0	-15.69M
Cash from Financing	-7.95M	-23.32M	112.66M	-27K	179.68M	263K	14.54M	135.34M	15.97M	5.19M
Debt Issued (Net)	0	0	143.75M	0	0	0	0	-38.66M	0	0
Equity Issued (Net)	440K	-1000K	-1000K	118K	1000K	0	1000K	1000K	1000K	2.69M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	-22.36M	-27.64M	0	0	0	0	0	0	0
Other Financing	-8.39M	-1.36M	-4.03M	-145K	0	263K	-10.78M	27.94M	6.72M	815.49K
Net Change in Cash	-25.85M▲ 0%	-22.65M▲ 12.4%	-7.24M▲ 68.0%	449K▲ 106.2%	61.95M▲ 13696.9%	-21.01M▼ 133.9%	23.27M▲ 210.7%	-42.81M▼ 284.0%	20.2M▲ 147.2%	51.23M▲ 0%
Free Cash Flow	17.7M▲ 0%	-37.04M▼ 309.3%	-102.89M▼ 177.8%	-38.35M▲ 62.7%	-48.83M▼ 27.3%	-77.34M▼ 58.4%	-71.02M▲ 8.2%	-128.51M▼ 81.0%	-46.91M▲ 63.5%	35.41M▲ 0%
FCF Margin %	11.78%	-21.44%	-99.64%	-64.77%	-218.64%	-	-	-459.58%	-27.74%	14.25%
FCF Growth %	-78.59%	-309.27%	-177.79%	62.72%	-27.32%	-58.37%	8.17%	-80.95%	63.5%	142.76%
FCF per Share	0.43	-0.89	-2.76	-1.03	-0.89	-1.32	-1.18	-1.60	-0.49	-0.49
FCF Conversion (FCF/Net Income)	-0.46x	0.25x	0.87x	1.15x	-6.93x	1.00x	0.51x	0.80x	0.96x	-127.36x
Interest Paid	788K	1.05M	3.36M	6.47M	6.47M	6.47M	0	0	0	5.84M
Taxes Paid	27.18M	19.14M	776K	140K	0	76K	0	0	0	0

AVDL Key Ratios

Avadel Pharmaceuticals plc (AVDL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	TTM
Return on Equity (ROE)	-75.09%	106.22%	-218.23%	-	10.56%	-64.3%	-481.49%	-481.35%	-60.44%	-0.33%
Return on Invested Capital (ROIC)	-98.15%	184.12%	-88.64%	-18.55%	2.84%	-32.6%	-70.93%	-217.45%	-76.28%	-76.28%
Gross Margin	91.18%	90.56%	83.04%	79.52%	74.29%	-	-	96.97%	90.97%	94.47%
Net Margin	-27.47%	38.93%	-92.29%	-56.11%	31.47%	-	-	-573.17%	-28.87%	-0.11%
Debt / Equity	0.02x	0.00x	41.67x	-	0.80x	1.85x	-	0.03x	0.02x	0.02x
Interest Coverage	-5.16x	83.94x	-9.88x	-1.93x	0.45x	-8.60x	-7.99x	-13.94x	-3.91x	0.66x
FCF Conversion	-0.46x	0.25x	0.87x	1.15x	-6.93x	1.00x	0.51x	0.80x	0.96x	-127.36x
Revenue Growth	-13.26%	14.97%	-40.22%	-42.66%	-62.28%	-100%	-	-	504.79%	79.88%

AVDL SEC Filings & Documents

Avadel Pharmaceuticals plc (AVDL) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Feb 12, 2026·SEC

Material company update

Jan 20, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

FY 2025

Mar 3, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 4, 2025·SEC

FY 2025

Aug 7, 2025·SEC

FY 2025

May 7, 2025·SEC

AVDL Frequently Asked Questions

Avadel Pharmaceuticals plc (AVDL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Avadel Pharmaceuticals plc (AVDL) reported $248.5M in revenue for fiscal year 2024. This represents a 4972% increase from $4.9M in 1996.

Avadel Pharmaceuticals plc (AVDL) grew revenue by 504.8% over the past year. This is strong growth.

Avadel Pharmaceuticals plc (AVDL) reported a net loss of $0.3M for fiscal year 2024.

Dividend & Returns

Avadel Pharmaceuticals plc (AVDL) has a return on equity (ROE) of -60.4%. Negative ROE indicates the company is unprofitable.

Avadel Pharmaceuticals plc (AVDL) generated $35.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More AVDL

Avadel Pharmaceuticals plc (AVDL) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Avadel Pharmaceuticals plc(AVDL)Earnings, Financials & Key Ratios

AVDL Key Insights

✓Strengths

✗Weaknesses

AVDL Price & Volume

AVDL Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

AVDL Recent Earnings

AVDL Peer Comparison

Compare AVDL vs Peers

vs JAZZ

vs MCK

Compare Top 5

AVDL Income Statement

AVDL Balance Sheet

AVDL Cash Flow Statement

AVDL Key Ratios

AVDL SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

AVDL Frequently Asked Questions

Explore More AVDL

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation